MedTrace Logo

A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma

NCT05147558 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-27

No results posted yet for this study

Summary

The purpose of this study to find out whether the combination of lenvatinib and pembrolizumab is an effective treatment for advanced uterine carcinosarcoma. The researchers will also do tests to find out whether biomarkers in the blood can predict the cancer's response to the study treatment. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition

Conditions

  • Uterine Carcinosarcoma
  • Advanced Uterine Carcinosarcoma

Interventions

DRUG

Pembrolizumab

Pembrolizumab (200mg every 3 weeks, intravenously)

DRUG

Lenvatinib

Lenvatinib (20mg once daily orally)

Sponsors & Collaborators

Principal Investigators

  • Vicky Makker, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-23
Primary Completion
2026-12-23
Completion
2026-12-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05147558 on ClinicalTrials.gov